TY - JOUR
T1 - A nationwide survey of rapidly progressive glomerulonephritis in Japan
T2 - Etiology, prognosis and treatment diversity
AU - Koyama, Akio
AU - Yamagata, Kunihiro
AU - Makino, Hirofumi
AU - Arimura, Yoshihiro
AU - Wada, Takashi
AU - Nitta, Kosaku
AU - Nihei, Hiroshi
AU - Muso, Eri
AU - Taguma, Yoshio
AU - Shigematsu, Hidekazu
AU - Sakai, Hideto
AU - Tomino, Yasuhiko
AU - Matsuo, Seiichi
N1 - Funding Information:
We express our thanks to the doctors who participated with this observational study (listed in Table ). The authors also express their gratitude to Ms. Yuko Sudo, Ms Keiko Fujioka, and Ms. Sanae Hasegawa for manuscript preparation, as well as to Dr. Hideto Takahashi for statistical analysis, and to Dr. Kouichi Hirayama, Dr. Kaori Mase, Dr. Naoto Yamaguchi, Dr. Chie Saitoh, Dr. Joichi Usui and Dr. Masaki Kobayashi for valuable discussion and preparation of data. This study was supported in part by a grant in relation to Progressive Renal Disease from the Ministry of Health, Labor and Welfare Research Project for Specially Selected Disease.
PY - 2009/12
Y1 - 2009/12
N2 - Background: The etiology, prevalence, and prognosis of rapidly progressive glomerulonephritis (RPGN) including renal vasculitis vary among races and periods. Method: To improve the prognosis of Japanese RPGN patients, we conducted a nationwide survey of RPGN in the nephrology departments of 351 tertiary hospitals, and found 1772 patients with RPGN (Group A: diagnosed between 1989 and 1998, 884 cases; Group B: diagnosed between 1999 and 2001, 321 cases; and Group C: diagnosed between 2002 and 2007, 567 cases). ANCA subclasses, renal biopsy findings, treatment, outcome and cause of death were recorded. Result: The most frequent primary disease was renallimited vasculitis (RLV) (42.1%); the second was microscopic polyangiitis (MPA) (19.4%); the third was anti-GBM-associated RPGN (6.1%). MPO-ANCA was positive in 88.1% of RLV patients and 91.8% of MPA patients. The proportion of primary renal diseases of RPGN was constant during those periods. The most frequent cause of death was infectious complications. The serum creatinine at presentation and the initial dose of oral prednisolone decreased significantly in Groups B and C compared to Group A. However, both patient and renal survival rates improved significantly in Groups B and C (survival rate after six months in Group A: 79.2%, Group B: 80.1%, and Group C: 86.1%. Six-month renal survival in Group A: 73.3%, Group B: 81.3%, and Group C: 81.8%). Conclusion Early diagnosis was the most important factor for improving the prognosis of RPGN patients. To avoid early death due to opportunistic infection in older patients, a milder immunosuppressive treatment such as an initial oral prednisolone dose reduction with or without immunosuppressant is recommended.
AB - Background: The etiology, prevalence, and prognosis of rapidly progressive glomerulonephritis (RPGN) including renal vasculitis vary among races and periods. Method: To improve the prognosis of Japanese RPGN patients, we conducted a nationwide survey of RPGN in the nephrology departments of 351 tertiary hospitals, and found 1772 patients with RPGN (Group A: diagnosed between 1989 and 1998, 884 cases; Group B: diagnosed between 1999 and 2001, 321 cases; and Group C: diagnosed between 2002 and 2007, 567 cases). ANCA subclasses, renal biopsy findings, treatment, outcome and cause of death were recorded. Result: The most frequent primary disease was renallimited vasculitis (RLV) (42.1%); the second was microscopic polyangiitis (MPA) (19.4%); the third was anti-GBM-associated RPGN (6.1%). MPO-ANCA was positive in 88.1% of RLV patients and 91.8% of MPA patients. The proportion of primary renal diseases of RPGN was constant during those periods. The most frequent cause of death was infectious complications. The serum creatinine at presentation and the initial dose of oral prednisolone decreased significantly in Groups B and C compared to Group A. However, both patient and renal survival rates improved significantly in Groups B and C (survival rate after six months in Group A: 79.2%, Group B: 80.1%, and Group C: 86.1%. Six-month renal survival in Group A: 73.3%, Group B: 81.3%, and Group C: 81.8%). Conclusion Early diagnosis was the most important factor for improving the prognosis of RPGN patients. To avoid early death due to opportunistic infection in older patients, a milder immunosuppressive treatment such as an initial oral prednisolone dose reduction with or without immunosuppressant is recommended.
KW - Anti-neutrophil cytoplasmic antibody (ANCA)
KW - Microscopic polyangiitis (MPA)
KW - Myeloperoxidase (MPO)
KW - RPGN clinical grading system
KW - Rapidly progressive glomerulonephritis (RPGN)
KW - Renal vasculitis
UR - http://www.scopus.com/inward/record.url?scp=76249092630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76249092630&partnerID=8YFLogxK
U2 - 10.1007/s10157-009-0201-7
DO - 10.1007/s10157-009-0201-7
M3 - Article
C2 - 19533266
AN - SCOPUS:76249092630
SN - 1342-1751
VL - 13
SP - 633
EP - 650
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 6
ER -